Generic Drug Price-Fixing Settlements: Claims Due March 8, 2027

Key facts

What is open: A consumer claim process tied to multistate generic-drug antitrust settlements
Who may qualify: People who purchased certain listed generic prescription drugs between May 2009 and December 2019
Claim deadline: March 8, 2027
Settlement money secured: More than $96 million from Apotex, Heritage Pharmaceuticals, Bausch, Lannett, and Glenmark Pharmaceuticals USA
Court: U.S. District Court for the District of Connecticut, according to the current state attorney general announcement
Current status: The distribution plan received preliminary approval. Related multistate litigation against other companies and executives continues.

What changed

A court-approved consumer claim process is now open in litigation over alleged price fixing in the generic prescription drug industry. The New York Attorney General announced on September 22, 2026 that the U.S. District Court for the District of Connecticut had preliminarily approved a plan to distribute tens of millions of dollars to eligible consumers. Claims must be submitted by March 8, 2027.

The process is connected to settlements totaling more than $96 million with five generic-drug manufacturers: Apotex, Heritage Pharmaceuticals, Bausch, Lannett, and Glenmark Pharmaceuticals USA. The states say the money was secured through a series of settlements in broader litigation alleging that manufacturers coordinated prices, bids, and market shares for more than 100 generic drugs.

Consumers can review the drug list and submit through the official administrator site at AGGenericDrugs.com. The New York Attorney General also lists the administrator's toll-free number, 1-866-290-0182, and email address, info@aggenericdrugs.com.

Deadline to act

Eligible consumers must submit a claim by March 8, 2027. The official administrator, not Class Action Pulse, determines whether a purchase is covered and whether a claim is valid.

Who may be eligible

The current state announcement says consumers who purchased certain generic prescription drugs between May 2009 and December 2019 may be eligible. Earlier settlement announcements direct consumers to the same administrator site to check the covered drug list and their eligibility.

That date range and the phrase "certain generic prescription drugs" both matter. The process is not described as compensation for every person who bought any generic medication during those years. Eligibility depends on the products covered by the settlements and the rules in the court-approved distribution plan.

A generic drug is a medication approved to be marketed as an equivalent to a brand-name drug in dosage form, strength, route of administration, quality, performance characteristics, and intended use. Generic competition generally lowers prices after brand exclusivity ends. The states allege that the challenged coordination interfered with that competition for covered products.

The New York Attorney General says the affected drugs include tablets, capsules, creams, and ointments used for conditions that range from infections and attention-deficit/hyperactivity disorder to diabetes, cancer, epilepsy, multiple sclerosis, and HIV. One example cited by the office is digoxin, a heart medication that the state says tripled in price.

Check the product list

A purchase during the 2009 to 2019 period does not by itself establish eligibility. Claimants should match their medication and purchase history against the official administrator's covered-drug list and instructions.

What the generic-drug cases allege

The settlements arise from three lawsuits brought by bipartisan coalitions of state attorneys general. The first complaint was filed in 2016 and addressed 15 generic drugs. A second complaint filed in 2019 named major generic-drug manufacturers and individual executives. A third complaint filed in 2020 focused on 80 primarily topical generic drugs, including creams, gels, lotions, ointments, shampoos, and solutions.

The complaints allege a broad conspiracy to fix prices, allocate markets, avoid competition, and rig bids. In antitrust law, price fixing means an agreement among competitors about prices or price-related terms instead of independent competition. Market allocation means competitors allegedly divide customers, products, or territories rather than competing for them. Bid rigging means competitors allegedly coordinate bids so the process does not reflect genuine competition.

According to the state attorneys general, executives communicated through calls, emails, text messages, industry dinners, lunches, cocktail events, and golf outings. The states say participants used phrases such as "fair share," "playing nice in the sandbox," and "responsible competitor" when discussing conduct the complaints characterize as limiting competition.

The 2024 state announcement says the investigation relied on cooperating witnesses, more than 20 million documents, and a phone-record database covering millions of call details and contacts for more than 600 sales and pricing personnel. Those statements describe the states' investigative record. They do not mean every allegation against every remaining defendant has been adjudicated.

Who the settling companies are

Apotex, Heritage Pharmaceuticals, Bausch, Lannett, and Glenmark Pharmaceuticals USA manufacture or distribute generic medicines. They entered settlements at different points in the continuing multistate cases.

Apotex and Heritage were the first two companies in this settlement group. State attorneys general announced agreements totaling $49.1 million in November 2024. The states said both companies agreed to cooperate in the continuing litigation and make internal changes designed to support antitrust compliance.

Bausch and Lannett followed in February 2026. The state announcement assigns $13.77 million to Lannett and $4.08 million to Bausch, for $17.85 million combined. The companies also agreed to antitrust compliance programs and annual training for sales and management employees.

Glenmark's settlement was announced in July 2026. The New York Attorney General says Glenmark will pay $25 million with interest over four years, for a stated total of $29.668 million, and cooperate in the continuing cases.

Together, the announced figures exceed $96 million. The settlements resolve claims against these companies under their agreements, but they do not end the broader litigation against other corporate and individual defendants.

How generic-drug pricing works

Generic medicines are intended to provide lower-cost alternatives to brand-name products after the relevant patent and exclusivity protections allow competition. Multiple manufacturers may make versions of the same active ingredient. In a competitive market, manufacturers independently decide whether to enter, how much product to supply, and what prices or bids to offer wholesalers, pharmacies, insurers, government programs, and other purchasers.

The states' theory is that competitors did not always make those decisions independently. The complaints allege manufacturers coordinated price increases, avoided competing for certain customers, and maintained expected market shares. If proved, that conduct can violate federal and state antitrust laws because it replaces competition with agreement.

The practical consumer effect depends on how a prescription was paid. A person may have paid a cash price, a copayment, coinsurance, or another out-of-pocket amount. Insurers and government programs may also have paid part of the drug's cost. The current public state announcement does not provide a universal formula for translating a purchase into an individual settlement payment.

Settlement amounts and payment limits

The five settling manufacturers have agreed to payments totaling more than $96 million. The September 2026 announcement says the preliminarily approved plan will distribute tens of millions of dollars to consumers who overpaid for covered generic drugs.

That does not establish a fixed payment for each claimant. The final amount may depend on the court-approved plan, the claimant's covered purchases, available records, the number and value of valid claims, administration expenses, and any other allocations approved by the court. The current attorney general announcement does not promise a minimum check or a set percentage of a person's drug costs.

Consumers should be cautious with headlines that divide the total settlement by an assumed number of claimants. The official materials reviewed for this article do not support that calculation. A valid claim may receive a different amount from another valid claim, and payment cannot be guaranteed before the administrator completes review and the settlement process reaches the required stage.

No fixed payout is verified

More than $96 million has been secured across the five settlements, but the current official announcement does not state a guaranteed individual payment. Do not estimate a check by dividing the fund by an assumed class size.

Case timeline and current status

2009 to 2019: The current eligibility guidance covers purchases of listed generic drugs during this period.
December 2016: The first multistate complaint was filed over alleged coordination involving 15 generic drugs.
May 2019: The states filed a second complaint against major generic manufacturers and individual executives.
June 2020: The states filed a third complaint focused on 80 primarily topical generic drugs.
November 2024: Apotex and Heritage settlements totaling $49.1 million were announced.
February 2026: Bausch and Lannett settlements totaling $17.85 million were announced.
July 2026: The Glenmark settlement, stated at $29.668 million with interest over four years, was announced.
September 22, 2026: The New York Attorney General announced preliminary approval of the consumer distribution plan and the March 8, 2027 claim deadline.
March 8, 2027: Consumer claim deadline.

The litigation remains active against other defendants. The current announcement says settling companies agreed to cooperate in those continuing cases. Preliminary approval allows notice and claims administration to proceed, but it is not the same as a final merits judgment against all defendants.

How to file a claim

Consumers should use the official administrator website, AGGenericDrugs.com, to review the covered-drug list, eligibility rules, and claim instructions. The New York Attorney General says consumers may also request a form or help by calling 1-866-290-0182 or emailing info@aggenericdrugs.com.

Before starting, a claimant may want to gather pharmacy receipts, insurer explanations of benefits, prescription histories, or other records that identify the drug, purchase date, and out-of-pocket payment. The administrator's current form and instructions control what proof is required. Class Action Pulse does not process these claims and should not receive medical, insurance, prescription, or payment records.

Keep a copy of the submitted form and the confirmation. Use the administrator's contact information if the official drug list or form does not answer a question. Do not pay an unrelated person to file a claim, and do not send health or financial information through unofficial links.

Use the official process

Submit only through the court-authorized administrator or the contact methods published by a participating state attorney general. Keep the confirmation and any records used to support the claim.

What remains disputed or unresolved

The public record reviewed for this article does not establish a final individual payment formula or guaranteed payout. It also does not show that the continuing claims against every nonsettling company or executive have been decided. The states describe their allegations and investigative evidence, while the settlements resolve claims against the settling manufacturers under negotiated terms.

The broader cases concern different drug groups, defendants, and time periods. A consumer's eligibility for this distribution therefore depends on the administrator's list and plan, not merely on having purchased a generic prescription.

The administrator site temporarily blocked automated retrieval during this reporting run. The claim deadline, covered purchase window, settlement totals, official website, phone number, email address, and preliminary-approval posture were independently confirmed through the New York Attorney General's current and prior official announcements. Claimants should recheck the administrator site for the controlling form, drug list, and any updated dates before submitting.

Frequently asked questions

Who can submit a claim?

Consumers who purchased certain listed generic prescription drugs between May 2009 and December 2019 may be eligible. The administrator's covered-drug list and claim rules control.

What is the claim deadline?

The current New York Attorney General announcement lists March 8, 2027 as the deadline.

How much money could I receive?

The official state announcement reviewed for this article does not state a guaranteed individual amount. Payments may depend on covered purchases, valid claims, available funds, and the court-approved distribution plan.

Do I need proof of purchase?

The administrator's form and instructions determine what records are required. Pharmacy, insurer, or prescription-history records may help identify covered purchases, but claimants should follow the official instructions rather than assume a particular document is sufficient.

Is this a settlement with every company named in the generic-drug cases?

No. The current claim process is tied to settlements with Apotex, Heritage, Bausch, Lannett, and Glenmark. The state attorneys general say litigation continues against other corporate and individual defendants.

Did a court find that every allegation was true?

No. The current distribution plan has preliminary approval, and the settlements resolve claims against particular companies. Allegations against remaining defendants are not the same as final findings.

Where should I file?

Use AGGenericDrugs.com or the administrator contact information published by a participating attorney general. Do not send prescription or payment records to Class Action Pulse.